These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 17270637)

  • 41. Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer.
    Gennari A; Guarneri V; Landucci E; Orlandini C; Rondini M; Salvadori B; Ricci S; Conte PF
    Clin Breast Cancer; 2002 Dec; 3(5):346-52. PubMed ID: 12533265
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A phase II study of estramustine, docetaxel, and exisulind in patients with hormone- refractory prostate cancer: results of cancer and leukemia group B trial 90004.
    Dawson NA; Halabi S; Ou SS; Biggs DD; Kessinger A; Vogelzang N; Clamon GH; Nanus DM; Kelly WK; Small EJ;
    Clin Genitourin Cancer; 2008 Sep; 6(2):110-6. PubMed ID: 18824434
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical significance of a prostate-specific antigen flare phenomenon in patients with hormone-refractory prostate cancer receiving docetaxel.
    Olbert PJ; Hegele A; Kraeuter P; Heidenreich A; Hofmann R; Schrader AJ
    Anticancer Drugs; 2006 Sep; 17(8):993-6. PubMed ID: 16940810
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
    Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A
    Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phase II trial of neoadjuvant chemotherapy with docetaxel followed by epirubicin in stage II/III breast cancer.
    Ramaswamy B; Povoski SP; Rhoades C; Allen J; Hauger M; Young D; Burak W; Farrar W; Yee L; Kendra K; Somasundaram S; Orlowski RZ; Shapiro CL
    Breast Cancer Res Treat; 2005 Sep; 93(1):67-74. PubMed ID: 16184461
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer.
    Montgomery RB; Nelson PS; Lin D; Ryan CW; Garzotto M; Beer TM
    Cancer; 2007 Sep; 110(5):996-1002. PubMed ID: 17639587
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators.
    Beer TM; Ryan CW; Venner PM; Petrylak DP; Chatta GS; Ruether JD; Redfern CH; Fehrenbacher L; Saleh MN; Waterhouse DM; Carducci MA; Vicario D; Dreicer R; Higano CS; Ahmann FR; Chi KN; Henner WD; Arroyo A; Clow FW;
    J Clin Oncol; 2007 Feb; 25(6):669-74. PubMed ID: 17308271
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Weekly epidoxorubicin therapy in hormone-refractory metastatic prostate cancer.
    Neri B; Barbagli G; Bellesi P; Di Loro R; Lombardi V; Lombardo C; Magrini T; Mottola A; Nicita G; Palminteri E; Ponchietti R; Raugei A; Intini C
    Anticancer Res; 1997; 17(5B):3817-20. PubMed ID: 9427786
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Weekly administration of docetaxel and epirubicin as first-line treatment for hormone-refractory prostate carcinoma.
    Neri B; Molinara E; Pantaleo P; Rangan S; Crisci A; Della Melina A; Raugei A; Villari D; Nicitat G
    Oncol Res; 2009; 17(11-12):565-70. PubMed ID: 19806787
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Weekly paclitaxel and epirubicin in the treatment of symptomatic hormone-refractory advanced prostate carcinoma: report of a phase II trial.
    Neri B; Cipriani G; Fulignati C; Turrini M; Ponchietti R; Bartoletti R; Della Melina A; Di Cello V; Dominici A; Maleci D; Raugei A; Villari D; Nicita G
    Anticancer Drugs; 2005 Jan; 16(1):63-6. PubMed ID: 15613906
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Biweekly doxorubicin/ketoconazole as second-line treatment in docetaxel-resistant, hormone-refractory prostate cancer.
    Lainakis G; Nikos A; Gerassimos A; Michael C; Iraklis M; Konstantinos L; Ioannis V; Harilaos K; Dimopoulos MA; Bamias A
    Urology; 2008 Jun; 71(6):1181-5. PubMed ID: 18400264
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Suramin in combination with weekly epirubicin for patients with advanced hormone-refractory prostate carcinoma.
    Falcone A; Antonuzzo A; Danesi R; Allegrini G; Monica L; Pfanner E; Masi G; Ricci S; Del Tacca M; Conte P
    Cancer; 1999 Aug; 86(3):470-6. PubMed ID: 10430255
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bi-weekly epirubicin, etoposide and low-dose dexamethasone for hormone-refractory prostate cancer.
    Odrazka K; Vaculikova M; Petera J; Moravek P; Prosvic P; Zoul Z; Rydel L; Brodak M; Veselsky Z; Louda M; Simakova E
    Int J Urol; 2003 Jul; 10(7):387-91. PubMed ID: 12823694
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study.
    Petrioli R; Pascucci A; Conca R; Chiriacò G; Francini E; Bargagli G; Fiaschi AI; Manganelli A; De Rubertis G; Barbanti G; Ponchietti R; Francini G
    Br J Cancer; 2011 Feb; 104(4):613-9. PubMed ID: 21285986
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Combination chemotherapy with docetaxel and cisplatin in patients with hormone-refractory prostate cancer].
    Fujinami K; Miura T; Takizawa A; Osada Y
    Hinyokika Kiyo; 2005 Jan; 51(1):5-8. PubMed ID: 15732332
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [AUO study in hormone-refractory prostate cancer. Phase III study on treatment of hormone-refractory prostate cancer (HRPC) with docetaxel: continuous treatment vs. intermittent repetition of treatment after renewed progression--PRINCE].
    Rexer H
    Urologe A; 2006 Jul; 45(7):872. PubMed ID: 16791626
    [No Abstract]   [Full Text] [Related]  

  • 57. Real-world uptake, safety profile and outcomes of docetaxel in newly diagnosed metastatic prostate cancer.
    Rulach RJ; McKay S; Neilson S; White L; Wallace J; Carruthers R; Lamb C; Cascales A; Marashi H; Glen H; Venugopal B; Sadoyze A; Sidek N; Russell JM; Alhasso A; Dodds D; Laskey J; Jones RJ; MacLeod N
    BJU Int; 2018 Feb; 121(2):268-274. PubMed ID: 28940952
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dose-finding study of weekly docetaxel plus estramustine in patients with hormone-refractory metastatic prostate cancer.
    Coccaro M; Tartarone A; Romano G; Ardito R; Di Renzo N
    Tumori; 2005; 91(4):314-6. PubMed ID: 16277095
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Weekly low-dose docetaxel in advanced hormone-resistant prostate cancer patients previously exposed to chemotherapy.
    Petrioli R; Pozzessere D; Messinese S; Sabatino M; Di Palma T; Marsili S; Correale P; Manganelli A; Salvestrini F; Francini G
    Oncology; 2003; 64(4):300-5. PubMed ID: 12759524
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Combination of epirubicin and cisplatin in hormone-refractory metastatic prostate cancer.
    Huan SD; Stewart DJ; Aitken SE; Segal R; Yau JC
    Am J Clin Oncol; 1999 Oct; 22(5):471-4. PubMed ID: 10521061
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.